Statin use may reduce lower extremity peak force via reduced engagement in muscle-strengthening activities

Clinical Physiology and Functional Imaging

Volumn 38, Issue 1, 2018, Pages 151-154

  Loenneke, Jeremy P ^a   Loprinzi, Paul D ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

epidemiology; function; myopathy; statin; strength

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; JOINT FUNCTION; LEG MUSCLE; MAJOR CLINICAL STUDY; MALE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; MUSCLE TRAINING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANGE OF MOTION; RESISTANCE TRAINING; CHEMICALLY INDUCED; DRUG EFFECT; LOWER LIMB; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCLE CONTRACTION; MYALGIA; NUTRITION; ODDS RATIO; PATHOPHYSIOLOGY; RISK FACTOR; SKELETAL MUSCLE; STATISTICAL MODEL; TIME FACTOR; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LINEAR MODELS; LOWER EXTREMITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCLE, SKELETAL; MYALGIA; NUTRITION SURVEYS; ODDS RATIO; RESISTANCE TRAINING; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84978648960     PISSN: 14750961     EISSN: 1475097X     Source Type: Journal    
DOI: 10.1111/cpf.12375     Document Type: Article

References (17)

1. Batista FS, Gomes GA, Neri AL, Sousa Mda L, D'Elboux MJ, et al. Relationship between lower-limb muscle strength and frailty among elderly people. Sao Paulo Med J (2012); 130: 102–108.
2. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther (2005); 19: 403–414.
3. Ditlevsen S, Christensen U, Lynch J, et al. The mediation proportion: a structural equation approach for estimating the proportion of exposure effect on outcome explained by an intermediate variable. Epidemiology (2005); 16: 114–120.
4. Fairchild AJ, Mackinnon DP, Taborga MP, et al. R2 effect-size measures for mediation analysis. Behav Res Methods (2009); 41: 486–498.
5. Freedman LS. Confidence intervals and statistical power of the “validation” ratio for surrogate or intermediate endpoints. J Stat Plan Inference (2001); 96: 143–153.
6. Hayes AF. Beyond Barron and Kenny: statistical mediation analysis in the new millennium. Commun Monogr (2009); 76: 408–420.
7. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol (2010); 21: 324–328.
8. Loprinzi PD, Sheffield J, Tyo BM, et al. Accelerometer-determined physical activity, mobility disability, and health. Disabil Health J (2014); 7: 419–425.
9. Loprinzi PD, Loenneke JP, Abe T. The association between muscle strengthening activities and red blood cell distribution width among a national sample of U.S. adults. Prev Med (2015); 73: 130–132.
10. Mansi I, Frei CR, Pugh MJ, et al. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med (2013); 173: 1–10.
11. Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve (2010); 42: 469–479.
12. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014); 370: 1422–1431.
13. Rizzoli R, Reginster JY, Arnal JF, et al. Quality of life in sarcopenia and frailty. Calcif Tissue Int (2013); 93: 101–120.
14. Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. In: Sociological Methodology (ed Leinhardt S) (1982), pp. 290–312. American Sociological Society, Washington, DC.
15. Stone NJ, Robinson JG, Lichtenstein AH, et al., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014); 63: 2889–2934.
16. Urso ML, Clarkson PM, Hittel D, et al. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol (2005); 25: 2560–2566.
17. Williams PT, Thompson PD. Effects of statin therapy on exercise levels in participants in the national runners' and walkers' health study. Mayo Clin Proc (2015); 90: 1338–1347.